Abstract: A magnetic locking device for a pipetting tool, the device having a plate that is able to be adapted to the pipetting tool, an accessory being intended to be fastened to a fastening end piece that is supported by the plate and/or intended to be supported by the pipetting tool. The device has at least one lock configured to switch from an active state to a passive state, and vice versa, such that, in the active state, the lock is able to block, in service, particles that are present in the accessory, and such that, in the passive state of the lock, the particles are free to move in the accessory.

Abstract: A method for iteratively autotuning a high-performance computing system that depends on a set of parameters. Performance is first evaluated two or more times with the current values of the parameters. Afterward at least two evaluations, the median performance is evaluated. The median is then tested against a rule based on a filtering threshold. If the median does not the rule, the current values of the parameters are discarded, and the method is restarted with at least one other value generated by an optimization module; otherwise, a resampling method is performed based on the median and on a confidence interval that decreases with the number of steps of the optimization method.

Abstract: Food supplements for bees that include molybdenum complexes and a method of administering the food supplements to the bees for preventing the infestation of bees and their larvae by the Varroa destructor mite. Also, the use of the food supplements to increase the production of honey and lower the winter mortality of bees.

Abstract: The invention relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers for amplifying said target fragment of the DNA sample including said microsatellite sequence; a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; and a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence. The invention also encompasses methods for the diagnosis and prognosis of cancer and a method for determining the efficacy of a cancer treatment.

Abstract: In the field of obesity related disease, identification of patients with nonalcoholic steatohepatitis (NASH) would be useful to counsel them more intensively on diet and lifestyle changes and propose new pharmacological treatments. As a consequence, the inventors worked on a method for post-processing images of a region of interest of the liver for reconstructing a map of the internal magnetic susceptibility by using a Bayesian regularization approach to inverse the internal magnetic field. Such method can be implemented on computer and provides better results than other known methods for obesity related disease. This method may be applied for predicting that a subject is at risk of suffering from such disease, diagnosing a disease, identifying a therapeutic or a biomarker and screening compounds useful as a medicine.

Abstract: A method for iteratively autotuning a high-performance computing system that depends on a set of parameters. Performance is first evaluated two or more times with the current values of the parameters. Afterward at least two evaluations, the median performance is evaluated. The median is then tested against a rule based on a filtering threshold. If the median does not the rule, the current values of the parameters are discarded, and the method is restarted with at least one other value generated by an optimization module; otherwise, a resampling method is performed based on the median and on a confidence interval that decreases with the number of steps of the optimization method.

Abstract: The present invention relates to a water-stable Titanium-based metal-organic framework (MOF) material having a high degree of condensation, i.e. an oxo to Ti ratio (or oxo to metal ratio, in the case of doped Ti-based MOFs) >1.0; a process of preparing same and uses thereof, particularly for heterogeneously catalyzed chemical reactions, for gas storage/separation/purification, for information storage, laser printing or as an oxygen indicator, or as proton conductive material (fuel cells), optoelectronic material (photovoltaic cells including Grätzel cells), as a matrix for encapsulating active principles (medicaments, cosmetics), or else as sensing material.

Abstract: The present invention relates to an in vitro method for identifying and/or characterizing one or more mutations in a hotspot mutation sequence of at least one ESR1 target fragment from a DNA sample, said method comprising subjecting the DNA sample to a drop-off digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers suitable for amplifying an ESR1 target fragment; an oligonucleotide reference (REF) hydrolysis probe, labeled with a fluorophore, wherein said REF oligonucleotide probe is complementary to a wild-type sequence of the target fragment located outside of the hotspot mutation sequence; an oligonucleotide hotspot (HOTSPOT) hydrolysis probe, labeled with another fluorophore, wherein said oligonucleotide HOTSPOT probe is complementary to a wild-type sequence of the hotspot mutation sequence of the target DNA fragment.

Abstract: The invention relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers for amplifying said target fragment of the DNA sample including said microsatellite sequence; a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence. The invention also encompasses methods for the diagnosis and prognosis of cancer and a method for determining the efficacy of a cancer treatment.

Abstract: The present invention concerns metal-organic hybrid solids having a modified outer surface. These solids can be used, for example, for the storage and vectoring of molecules of interest such as pharmaceutically active ingredients, compounds of interest in cosmetics and markers, for example contrast agents. These solids have good results in terms of active drug loading capacities, biocompatibility, stability and controlling the release of the active ingredients encapsulated.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the present invention relates to a method for increasing the amount of functional FECH in a erythroid cell carrying the hypomorphic allele IVS3 48C/T (rs2272783) in trans to a deleterious mutation in the FECH gene comprising the step of consisting of bringing the erythroid cell into contact with at least one antisense oligonucleotide (ASO) comprising the sequence as set forth by SEQ ID NO: 2 (5? gcagcctgagaaatgtttt 3?) to prevent splicing of the cryptic exon inserted into the mutant IVS3 48C/T (rs2272783) FECH mRNA.

Abstract: Method for preparing a homogeneous collagen-based material by concentration of a collagen solution, includes bringing a collagen solution into contact by way of continuous injection and use of the material for tissue repair.

Abstract: ANT-ligands having a substituted nitrogeneous heterocycle A wherein A is a substituted pyrimidinone of formula I wherein R1 is —(CH2)n-CO—OH; —(CH2)n-CO—OR; —(CH2)n-CO—NHR; —(CH2)n-CO—N(R, R?); —(CH2)n-OH; —(CH2)n-OR; —(CH2)n-OAr; —(CH2)n-C(R,R?)—(CH2)n-OH, R and R?, in the above radicals, being identical or different and representing H or a C1-C12 alkyl or cycloalkyl radical; and Ar is a phenyl or Het., Het.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the present invention relates to a method for increasing the amount of functional FECH in a erythroid cell carrying the hypomorphic allele IVS3 48C/T (rs2272783) in trans to a deleterious mutation in the FECH gene comprising the step of consisting of bringing the erythroid cell into contact with at least one antisense oligonucleotide (ASO) comprising the sequence as set forth by SEQ ID NO: 2 (5? gcagcctgagaaatgtttt 3?) to prevent splicing of the cryptic exon inserted into the mutant IVS3 48C/T (rs2272783) FECH mRNA.

Abstract: The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (CD31+/41?), pan-leukocyte (CD11a+), lymphocyte (CD4+), erythrocyte (CD235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.

Abstract: The invention relates to a method for determining the maximum open circuit voltage and the power that can be output by a photoconverter material subject to a measurement light intensity, the method including the following steps: measuring the photoluminescent intensity of the material, measuring the absorption rate of the photoconverter material at a second wavelength substantially equal to the photoluminescent wavelength of the photoconverter material, determining the maximum open circuit voltage of the photoconverter material with the measurement light intensity by means of the absorption rate and the photoluminescent intensity measured at substantially the same wavelength; said invention being characterized in that the light source and the photoconverter material are arranged such that the angular distributions of the rays incident on and emitted by the lit surface of the material and collected by the detector are substantially identical.

Abstract: A method for chemically passivating a surface of a product made of a III-V semiconductor material in which a) a P(N) polymer film is formed by deposition in a solvent comprising liquid ammonia. The film is formed by deposition, without electrochemical assistance, in the solvent, in the presence of an oxidizing chemical additive comprising phosphorous and generating electrical charge carriers in said surface.

Abstract: The present invention relates to a method for producing platelets from mature megakaryocytes. More particularly, the invention relates to an ex vivo method for producing platelets, from mature megakaryocytes, said method comprising a step of subjecting a suspension of mature megakaryocytes to a flow having a minimal shear rate of 600 s?1 on a solid phase coated with Von Willebrand factor.

Abstract: ANT-ligands having a substituted nitrogeneous heterocycle A wherein A is a substituted pyrimidinone of formula I wherein R1 is —(CH2)n-CO—OH; —(CH2)n-CO—OR; —(CH2)n-CO—NHR; —(CH2)n-CO—N(R, R?); —(CH2)n-OH; —(CH2)n-OR; —(CH2)n-OAr; —(CH2)n-C(R,R?)—(CH2)n-OH, R and R?, in the above radicals, being identical or different and representing H or a C1-C12 alkyl or cycloalkyl radical; and Ar is a phenyl or Het., Het.

Abstract: The invention relates to molecules ANT-ligands having a substituted nitrogeneous heterocycle A wherein A is a substituted pyrazinone of formula I wherein R1 is —(CH2)n—CO—OH; —(CH2)n—CO—OR; —(CH2)n—CO—NHR; —(CH2)n—CO—N(R,R?); —(CH2)n—OH; —(CH2)n—OR; —(CH2)n—OAr; —(CH2)n—C(R,R?)—(CH2)n—OH, R and R?, in the above radicals, being identical or different and representing H or a C1-C12 alkyl or cycloalkyl radical; and Ar is a phenyl or Het., Het.